Once strictly the domain of research labs, gene-sequencing tests increasingly are being used to help understand the genetic causes of rare disease, putting insurance companies in the position of deciding whether to pay the $5,000 to $17,000 for the tests.
As sequencing moves into clinical use, insurers balk
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.